Table 1.
General characteristics of the whole population.
| General population | Eutrophic | Overweight | Grade I obesity | Grade II obesity | |
|---|---|---|---|---|---|
| Number (n, %) | 242 | 85 (35.1%) | 90 (37.2%) | 43 (17.8%) | 17 (7%) |
| Age (years) | 62.6 (64–88) | 66.2 (58.7–74) | 61.5 (55.9–69.8) | 61.4 (53.1–69.9) | 61.1 (56.9–66.5) |
| Male sex (n, %) | 172 (71.1) | 59 (64.9) | 68 (75.6) | 30 (69.8) | 11 (64.7) |
| Hypertension (n, %) | 230 (95) | 78 (91.8) | 87 (96.7) | 42 (97.7) | 16 (94.4) |
| Diabetes mellitus (n, %) | 117 (48) | 29 (34.1)* | 46 (51.1) | 26 (60.5) | 13 (76.5) |
| Smoker (n, %) | 33 (13.6) | 14 (16.5) | 12 (13.3) | 6 (14) | 1 (5.9) |
| Alcoholism (n, %) | 44 (18.2) | 15 (17.6) | 18 (20) | 6 (14) | 5 (29.4) |
| COPD (n, %) | 11 (4.5) | 4 (4.7) | 3 (3.3) | 3 (7) | 1 (5.9) |
| Atrial fibrillation (n, %) | 54 (22.3) | 20 (23.5) | 18 (20) | 7 (16.3) | 6 (35.3) |
| CKD (n, %) | 66.5 (51.7–84.6) | 63.9 (44.7–82.8) | 70.4 (50–84) | 62.5 (39.4–75.5) | 62.9 (11.4–88.9) |
| Ejection fraction (%) | 35 (26–41) | 34 (25–41.7) | 35 (26–40) | 36 (29–42.5) | 37.5 (128–44.7) |
| NYHA I (n, %) | 26 (10.7) | 7 (8.2) | 12 (13.3) | 6 (14) | 1 (5.9) |
| NYHA II (n, %) | 115 (47.5) | 40 (47.1) | 42 (46.7) | 22 (51.2) | 6 (35.3) |
| NYHA III (n, %) | 77 (31.8) | 30 (35.3) | 29 (32.2) | 9 (20.9) | 7 (41.2) |
| NYHA IV (n, %) | 24 (9.9) | 8 (9.4) | 7 (7.8) | 6 (14) | 3 (17.6) |
| ARB/ACE-I/ARNI (n, %) | 207 (85.5) | 70 (82.3) | 82 (91.1) | 35 (81.4) | 14 (82.4) |
| MRA (n, %) | 118 (48.8) | 39 (45.9) | 46 (51.1) | 20 (46.5) | 10 (58.8) |
| Beta blockers (n, %) | 202 (83.5) | 70 (82.4) | 74 (82.2) | 36 (83.7) | 15 (82.2) |
| Mortality (n, %) | 121 (50) | 48 (56.4) | 39 (43.3) | 21 (48.8) | 9 (52.9) |
| MAGGIC score | 21 (16–27) | 22 (17–27) | 21 (15–28) | 21 (17–25) | 19 (14–28) |
Continuous variables are expressed as medians. Categorical variables are expressed as total number (%). CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ARB, angiotensin receptor blockers; ACE-I, angiotensin-converting enzyme inhibitors; ARNI, angiotensin receptor-neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
*
p < 0.05.